These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 20392582)

  • 21. Molecular mechanism of allosteric communication in the human PPARalpha-RXRalpha heterodimer.
    Venäläinen T; Molnár F; Oostenbrink C; Carlberg C; Peräkylä M
    Proteins; 2010 Mar; 78(4):873-87. PubMed ID: 19847917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
    Miyachi H
    IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.
    Oishi K; Uchida D; Ishida N
    FEBS Lett; 2008 Oct; 582(25-26):3639-42. PubMed ID: 18840432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
    Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
    Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
    Goetzman ES; Tian L; Wood PA
    Mol Genet Metab; 2005 Jan; 84(1):39-47. PubMed ID: 15639194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved.
    Osipova D; Kokoreva K; Lazebnik L; Golovanova E; Pavlov C; Dukhanin A; Orlova S; Starostin K
    Front Pharmacol; 2022; 13():797923. PubMed ID: 35359878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Metabolomics Approach to Investigate Kukoamine B-A Potent Natural Product With Anti-diabetic Properties.
    Li YY; Stewart DA; Ye XM; Yin LH; Pathmasiri WW; McRitchie SL; Fennell TR; Cheung HY; Sumner SJ
    Front Pharmacol; 2018; 9():1575. PubMed ID: 30723413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatty acid synthesis and PPARalpha hand in hand.
    Rotman N; Wahli W
    Chem Biol; 2009 Aug; 16(8):801-2. PubMed ID: 19716470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis.
    Chakravarthy MV; Pan Z; Zhu Y; Tordjman K; Schneider JG; Coleman T; Turk J; Semenkovich CF
    Cell Metab; 2005 May; 1(5):309-22. PubMed ID: 16054078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
    Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
    J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphatidylcholine and PPARalpha: a relevant connection in liver disease?
    Lamaziere A; Wolf C
    Gastroenterol Clin Biol; 2010; 34(4-5):250-1. PubMed ID: 20392582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous ligand for an orphan receptor.
    Wolf G
    Nutr Rev; 2010 May; 68(5):316-8. PubMed ID: 20500791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.